Unknown

Dataset Information

0

Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes.


ABSTRACT: BACKGROUND:We aimed to investigate in patients with type 2 diabetes whether aortic stiffness is: (i) associated with glycaemic control, (ii) associated with adverse outcomes and (iii) can be reversed on treatment with RAAS inhibition. METHODS:Patients with type 2 diabetes (N?=?94) and low vascular risk underwent assessment of cardiovascular risk and CMR assessment of ascending aortic distensibility (AAD), descending aortic distensibility (DAD) and aortic pulse wave velocity (PWV). Of these patients a subgroup with recent onset microalbuminuria (N?=?25) were treated with renin-angiotensin-aldosterone system (RAAS) inhibition and imaging repeated after 1 year. All 94 patients were followed up for 2.4 years for major adverse cardiovascular disease (CVD) events including myocardial infarction detected on late gadolinium enhancement CMR. RESULTS:Ascending aortic distensibility, DAD and PWV all had a significant association with age and 24 h systolic blood pressure but only AAD had a significant association with glycaemic control, measured as HbA1c (Beta - 0.016, P?=?0.04). The association between HbA1c and AAD persisted even after correction for age and hypertension. CVD events occurred in 19/94 patients. AAD, but not DAD or PWV, was associated with CVD events (hazard ratio 0.49, 95% confidence interval 0.25-0.95, P?=?0.01). On treatment with RAAS inhibition, AAD, but not DAD or PWV, showed significant improvement from 1.51?±?1.15 to 1.97?±?1.07 10-3 mmHg-1, P?=?0.007. CONCLUSIONS:Ascending aortic distensibility measured by CMR is independently associated with poor glycaemic control and adverse cardiovascular events. Furthermore it may be reversible on treatment with RAAS inhibition. AAD is a promising marker of cardiovascular risk in asymptomatic patients with type 2 diabetes and has potential use as a surrogate cardiovascular endpoint in studies of novel hypoglycaemic agents. Clinical trials registration https://clinicaltrials.gov/ct2/show/NCT01970319.

SUBMITTER: Swoboda PP 

PROVIDER: S-EPMC5836381 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes.

Swoboda Peter P PP   Erhayiem Bara B   Kan Rachel R   McDiarmid Adam K AK   Garg Pankaj P   Musa Tarique A TA   Dobson Laura E LE   Witte Klaus K KK   Kearney Mark T MT   Barth Julian H JH   Ajjan Ramzi R   Greenwood John P JP   Plein Sven S  

Cardiovascular diabetology 20180305 1


<h4>Background</h4>We aimed to investigate in patients with type 2 diabetes whether aortic stiffness is: (i) associated with glycaemic control, (ii) associated with adverse outcomes and (iii) can be reversed on treatment with RAAS inhibition.<h4>Methods</h4>Patients with type 2 diabetes (N = 94) and low vascular risk underwent assessment of cardiovascular risk and CMR assessment of ascending aortic distensibility (AAD), descending aortic distensibility (DAD) and aortic pulse wave velocity (PWV).  ...[more]

Similar Datasets

| S-EPMC6275449 | biostudies-literature
| S-EPMC7110673 | biostudies-literature
| S-EPMC6732913 | biostudies-literature
| S-EPMC2734562 | biostudies-literature
| S-EPMC4978311 | biostudies-literature
| S-EPMC5509300 | biostudies-literature
| S-EPMC7324609 | biostudies-literature
| S-EPMC4024466 | biostudies-literature
| S-EPMC4374835 | biostudies-literature
| S-EPMC8664762 | biostudies-literature